Glenmark Pharma launches EMI scheme for cancer patients

09 Feb 2016 Evaluate

Glenmark Pharma has rolled out an EMI scheme for cancer patients in order to help them continue the treatment and meet the high cost of medication. The company has included its two drugs - Abirapro prescribed for prostate cancer and Evermil, indicated for different cancers, such as breast and renal cell carcinoma - under the scheme.

Currently, Abirapro 250 mg in 120-pack size is priced at Rs 39,990. The drug in a 60-pack size costs Rs 19,995 and 30-pack size at Rs 9,998, while the company’s 10-tablet pack of 10 mg Evermil tablets is priced at Rs. 29,965 while the 5 mg tablets in 10 tablet pack is priced at Rs. 19,900.

Moreover, the company is planning to introduce a flexi payment scheme for other high-value cancer drugs very soon. Both Abirapro and Evermil need to be taken for long durations of time ranging from a few months to over a year or more. Both the drugs are critical for the survival of patients.

Glenmark Pharma Share Price

1943.35 9.10 (0.47%)
21-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.55
Dr. Reddys Lab 1155.50
Cipla 1369.55
Zydus Lifesciences 876.10
Lupin 2139.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×